

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.mspto.gov

	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/801,089	03/08/2001	David R. Phillips	44481-5008-02	7657
7590 08/06/2003 INTELLECTUAL PROPERTY GROUP			EXAMINER	
MILLENNIUM PHARMACEUTICALS, INC 75 SIDNEY STREET CAMBRIDGE, MA 02139			EWOLDT, GERALD R	
			ART UNIT	PAPER NUMBER
			1644 DATE MAILED: 08/06/2003	22

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

Applicant(s)

09/801,089

Phillips et al.

Examiner

G.R. Ewoldt, Ph.D.

Art Unit 1644



	The MAILING DATE of this communication appears on	the cover sheet with the correspondence address		
Period f	or Reply ORTENED STATUTORY PERIOD FOR REPLY IS SET TO	D EXPIRE 1 MONTH(S) FROM		
T115 N	ORTENED STATUTORY PERIOD FOR REPLY IS SET TO MAILING DATE OF THIS COMMUNICATION. ions of time may be evailable under the provisions of 37 CFR 1.136 (a). In no			
mailing - If the p - If NO p - Failure - Any re	date of this communication.  beriod for reply specified above is less than thirty (30) days, a reply within the seriod for reply is specified above, the maximum statutory period will apply and to reply within the set or extended period for reply will, by statute, cause the eply received by the Office later than three months after the mailing date of this patent term adjustment. See 37 CFR 1.704(b).	tetutory minimum of thirty (30) days will be considered timely. will expire SIX (6) MONTHS from the mailing date of this communication. pplication to become ABANDONED (35 U.S.C. § 133).		
Status				
1) 💢	Responsive to communication(s) filed on May 27, 20	03		
2a) 🗌	This action is <b>FINAL</b> . 2b) X This action			
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.			
Disposi	tion of Claims	the state of the section		
	Claim(s) <u>1-40</u>	is/are pending in the application.		
	4a) Of the above, claim(s) <u>1-20 and 24-29</u>	is/are withdrawn from consideration.		
5) 🗆	Claim(s)			
6) 🗆	Claim(s)			
7) 🗆	Claim(s)			
·	Claim(s)	are subject to restriction and/or election requirement.		
8) X				
• •	ation Papers			
	The specification is objected to by the Examiner.	accepted or h) objected to by the Examiner.		
10)└┘		accepted of by objected to by the Examinor.		
	Applicant may not request that any objection to the dr	is: a) $\square$ approved b) $\square$ disapproved by the Examine		
11)∐				
	If approved, corrected drawings are required in reply to			
12)		er.		
Priorit	y under 35 U.S.C. §§ 119 and 120  Acknowledgement is made of a claim for foreign pri	ority under 35 U.S.C. § 119(a)-(d) or (f).		
		only under do dioloi a violey to as the		
a)		heen received		
	2 Copies of the certified copies of the priority do	cuments have been received in this National Stage		
*	application from the International Burea See the attached detailed Office action for a list of the	e certified copies not received.		
	Acknowledgement is made of a claim for domestic			
	☐ The translation of the foreign language provisiona			
15) [	a decomposition of the state of	priority under 35 U.S.C. §§ 120 and/or 121.		
- •	ment(s)			
	Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).		
2)	Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)		
3)	Information Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Cther:		

2

Serial No. 09/801,089 Art Unit 1644

## DETAILED ACTION

- 1. Applicant's amendment, filed 5/27/03, reciting newly claimed species, has necessitated an additional species election.
- 2. This application contains inventions drawn to patentably distinct species. Applicant is required under 35 U.S.C. § 121 to elect:
- A) a single cell type, such as one of those listed in Claims 34, 35, 37, 39, or 40 (note that a "leukocyte" is not considered a specific cell type),
- B) and list all Claims readable thereon including those subsequently added. Currently Claims 21-33, 36, and 38 are generic.
- 3. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

The different cell types comprise different biological and physiological properties. For example, a tumor cell comprises a significantly different cell type than does platelet. Accordingly, the species are independent and patentable over one another.

- 4. Applicant is advised that the response to this requirement to be complete must include an election of the species to be examined even though the requirement be traversed.
- 5. Any inquiry concerning this communication from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973.

G.R. Ewoldt, Ph.D. Patent Examiner Technology Center 1600 August 05, 2003 1 Zuett